Voxelotor

沃塞洛托

Report date: 2024/09/26 15:10:49
NMEFirst In Class

Base Information

Drug NameVoxelotor
Drug Alias NameOxbrytaGTx-011GBT-440
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSickle haemoglobin modulators
TargetsSickle haemoglobin
Therapy Area/IndicationsHypoxiaLeg UlcerAnemia, Sickle Cell +[12
Global Approved IndicationsAnemia, Sickle CellAnemia, Hemolytic
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/11/25
Country/TerritoryCanadaUnited StatesNetherlands +[17
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGlobal Blood Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Europe Ma Eeig
Active IndicationsAnemia, Sickle CellAnemia, Hemolytic
Inactive IndicationsHypoxiaLeg UlcerCardiovascular Diseases +[10

Other Information

ATC CodeB03XA
Related LinksDrugBankKEGG